Best Practices in Early-Stage NSCLC 

Launch Date: August 30, 2021

Expire Date: March 31, 2022

Estimated Time to Complete: 60 minutes 

This educational activity is jointly provided by AXIS Medical Education and ACCC 

This educational activity is supported by educational grants from  

AstraZeneca Pharmaceuticals and Merck Sharp & Dohme Corp. 

Target audience:  The primary target audience for this activity comprises members of the interprofessional clinical cancer care team including, but not limited to, oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals who are involved in the care of patients with early stage NSCLC.  

Overview:   

According to the National Cancer Institute, about 80% of cancer patients in the US are treated by community oncologists. Community oncologists treat several types of cancers and see a large volume of patients. In 2019, the FDA approved 11 new therapeutic agents or expansions in indications for existing drugs used in oncology and hematology practice. With the evolving treatment landscape with several novel emerging therapies for patients with early stage non-small cell lung cancer (NSCLC), clinicians would highly benefit from discussions with knowledgeable experts and peers in order to gain a fuller understanding of optimal treatment selection and sequencing strategies, integration of new therapies into practice, and consensus-aligned management of treatment-related adverse events (AEs).  

 This activity will offer three text-based self-study chapters that cover the role of adjuvant targeted therapies, biomarker testing, and care coordination for patients diagnosed with early-stage NSCLC. Each chapter will offer a foundational review of the topic area with reinforcement questions, along with case presentations with learner challenges in a variety of interactive formats.   

Learning Objectives: 

Faculty: 

 ACCREDITED CONTINUING EDUCATION 

Accreditation Statement 

Credit Designation for Physicians 

AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Credit Designation for Pharmacists 

This application-based activity is approved for 1.0 contact hours of continuing pharmacy education credit JA4008106-9999-21-037-H01-P. 

Credit Designation for Nursing 

AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours. 

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity. 

AXIS Contact Information  

For information about the accreditation of this program please contact AXIS at info@axismeded.org. 

Disclosure of Conflicts of Interest  

AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.   

AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.  

The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Disclosure of Unlabeled Use  

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

System Requirements 

Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux  

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above. For video playback, install the latest version of Flash or Quicktime